Fig 1: Reduced endocannabinoid ‘tone’ in Akita-KPTCGLUT2−/− mice. Decreased levels of LC-MS/MS measured kidney endocannabinoids, AEA and 2-AG, from Akita-KPTCGLUT2−/− mice, compared to Akita-KPTCGLUT2+/+ WT animals (A,E), corresponding to the decreased kidney Nape-pld (B) and no change in Faah mRNA levels (C), and FAAH activity (D) as well as increased Mgll (F) and no changes in Dagla/b mRNA levels (G,H). Kidney CB1R (Cnr1) mRNA (I) and protein levels are shown in a representative immunoblot (J) and quantification (K). Kidney CB2R (Cnr2) mRNA expression levels (L). For A and E, n = 6 mice for the Akita-KPTCGLUT2+/+ group and n = 7 mice for the Akita-KPTCGLUT2−/− group. For B, F–I, and L, n = 8 mice for the Akita-KPTCGLUT2+/+ group and n = 7 mice for the Akita-KPTCGLUT2−/− group. For K, n = 4 mice for each group. Data represent the mean ± SEM and were analyzed by Unpaired Two-tailed Student’s t-test; Nonparametric Mann–Whitney test was used for unnormal distributed data. * p < 0.05, ** p < 0.01. AEA, Anandamide; 2-AG, 2-arachidonoylglycerol; Napepld, N-acyl phosphatidylethanolamine phospholipase D; Mgll, monoacylglycerol lipase; Cnr, cannabinoid receptor.